ReviewCommunications biology2026
BUB signaling in cancer and molecular insights into targeted therapies.
Review in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Spindle Assembly Checkpoint (SAC) is vital for proper chromosome segregation during cell division and for maintaining genomic integrity; its disruption can cause aneuploidy and tumors. The BUB gene family ensures SAC fidelity by regulating kinetochore-microtubule attachments and mitotic progression. Dysregulation leads to chromosomal instability (CIN), contributing to cancer progression, heterogeneity, metastasis, and therapy resistance. Beyond mitosis, BUB proteins influence DNA repair, chromatin remodeling, transcription, and immune responses. They interact with cell cycle and genome stability pathways, impacting cancer prognosis and therapy response. Research is ongoing to validate BUB proteins as biomarkers and develop inhibitors, possibly combined with immunotherapies or DNA-damaging agents for resistant tumors. This review summarizes their functions, highlighting their potential in personalized cancer treatment.
Indexed as
Identifiers
42888198What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.